Viralgen and Axovia Therapeutics enter partnership, target retinal dystrophy in Bardet-Biedl Syndrome

News
Article

The lead gene therapy candidate, AXV-101, is expected to enter clinical development in mid-2025

An illustration of a genetic DNA helix with a red target on it. Image credit: ©Елена Бутусова – stock.adobe.com

Viralgen and Axovia are developing an AAV9-based gene therapy for retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS). Image credit: ©Елена Бутусова – stock.adobe.com

Viralgen and Axovia Therapeutics are partnering to advance the development and manufacture of an AAV9-based investigational gene therapy aimed at treating retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS). The collaboration will give patients access to a dynamic investigational treatment with the potential to stop photoreceptor cell death and retinal degeneration, as well as halt vision loss.

According to a press release, the two companies will work together by using the codon-optimised BBS1 AAV9 vector to minimise the vision loss caused by the genetic defects in the BBS1 gene. The therapy will also be manufactured at Viralgen’s facility, capitalising on the company’s expertise in AAV and using the Pro10 cell line and manufacturing platform.

“As Axovia advances its pipeline of potential therapies addressing the genetic causes of blindness towards the clinic, we want to ensure we have appropriately scaled AAV manufacturing to support this effort, and are very happy to have partnered with Viralgen as our [Contract Development and Manufacturing Organisation],” said Victor Hernandez, co-founder and chief scientific officer. “Our lead programme, AXV-101, which is being developed to address retinal dystrophy associated with Bardet-Biedl Syndrome (BBS), is expected to enter clinical development in mid-2025, and we believe this partnership will ensure fast and efficient development as we seek to advance this therapy toward patients as soon as possible.”

“We are delighted to partner with Axovia and bring in our AAV manufacturing expertise. We are committed to supplying quality vectors and timely supply with the goal of providing disease-modifying treatment for patients affected by BBS1-related retinal dystrophy,” Jimmy Vanhove, CEO of Viralgen, said.

Reference

Viralgen and Axovia Partner to Manufacture an Investigational Gene Therapy for Retinal Dystrophy in Bardet-Biedl Syndrome (BBS) patients. Viralgen. Published January 22, 2025. Accessed January 27, 2025. https://viralgen.com/news/viralgen-and-axovia-partner-to-manufacture-an-investigational-gene-therapy-for-retinal-dystrophy-in-bardet-biedl-syndrome-bbs-patients

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.